報價延遲最少15分鐘:2026/03/22 22:42 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.87 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.59/-1.43
|
|
企業價值
210.16M
|
| 資產負債 |
|
每股賬面淨值
1.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.16M
|
|
每股收益
0.37
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focsued on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue. |
